Your browser doesn't support javascript.
loading
Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis.
Li, Huiping; Geng, Cuizhi; Zhao, Hongmei; Jiang, Hanfang; Song, Guohong; Zhang, Jiayang; Liu, Yaxin; Gui, Xinyu; Wang, Jing; Li, Kun; Tong, Zhongsheng; Zhao, Fangyuan; Yang, Junlan; Chen, Guoliang; Liu, Qianyu; Liang, Xu.
  • Li H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Geng C; Breast Disease Diagnostic and Therapeutic Center, the Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050019, China.
  • Zhao H; Department of General Surgery, Peking University Third Hospital, Beijing 100191, China.
  • Jiang H; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Song G; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Zhang J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Liu Y; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Gui X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Wang J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Li K; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Tong Z; Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 30060, China.
  • Zhao F; Department of the Public Health Sciences, University of Chicago, Chicago 60637, USA.
  • Yang J; Department of Medical Oncology, Chinese PLA General Hospital, Beijing 100853, China.
  • Chen G; Jiangsu Hengrui Medicine Co. Ltd., Shanghai 200120, China.
  • Liu Q; Jiangsu Hengrui Medicine Co. Ltd., Shanghai 200120, China.
  • Liang X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Chin J Cancer Res ; 33(2): 243-255, 2021 Apr 30.
Article en En | MEDLINE | ID: mdl-34158743
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Article